Needham downgraded Centessa (CNTA) to Hold from Buy after Eli Lilly (LLY) agreed to acquire all of the issued and to be issued share capital of Centessa for $38.00 in cash per share plus one non-transferrable contingent value right worth up to an aggregate of $9.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa downgraded to Equal Weight from Overweight at Stephens
- Eli Lilly to acquire Centessa for $38/share in cash plus one CVR
- Eli Lilly to acquire Centessa for $38.00 per share in cash plus one CVR
- CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Centessa’s ORX750 Poised as Potential Best-in-Class Orexin Agonist with Upcoming Phase 2a Catalyst and Favorable Risk–Reward